Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Intercell vaccine gets U.S. pediatric approval
May 21, 2013
 
(Reuters) - Austria's Intercell said on Tuesday it has won U.S. regulatory approval for pediatric use of its Ixiaro vaccine to protect against Japanese Encephalitis (JE), a step it had achieved in Europe in February.
"For the first time in nearly two years, a licensed vaccine will now be available to vaccinate traveling children and children of forward-deployed military personal in Asia as well against JE," Chief Executive Thomas Lingelbach said in a statement, calling the step a key growth element for the product.
 
New flu vaccine could offer lifetime protection
May 28, 2013
 
US scientists are hopeful they've developed a universal flu vaccine that offers long-term protection and will replace the annual jab.
The inoculation has not been possible before because the influenza virus constantly changes, meaning scientists have had to develop new vaccines every year.
But Dr Gary Nabel from drug company Sanofi believes he has developed a new solution that could protect against all flu viruses and stop new strains turning into pandemics. He hopes to begin clinical trials within two years.
"We can't say anything about the H7 virus without further human studies, but in either case, this technology can set the stage for developing universal flu vaccines of this type. It provides a foundation for building broader vaccine protection against emerging influenza viruses and other pathogens."
Dr Nabel studied six strains of the H1N1 influenza virus. They tested it on ferrets and got an immune response that was 10 times the current vaccine.
The study was published in the journal Nature.
 
Vaccine Blocks Hand, Foot, Mouth Disease
May 29, 2013
 
An inactivated vaccine against enterovirus (EV) 71 was effective and safe in a large phase III study of children in China, the trial investigators reported.
Overall, the efficacy of the vaccine was 90% (95% CI 67.1-96.9) for the hand, foot, and mouth form of the disease and 80% (95% CI 58.2-90.8) for any EV71-associated illness, according to Feng-Cai Zhu, MSc, of the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, and colleagues.
During the trial, serious adverse events occurred in 1.2% of children who received the vaccine and in 1.5% of those who received placebo, the researchers reported online in the Lancet.
 
Wuhan BravoBio is recruiting talents
May 31, 2013
 
Wuhan BravoBio, a member company of BravoBio, locates in the core region of BioLake and is recruiting talents for its vaccine business. Multiple positions are open currently with inspiring packages. http://www.bravobio.com/job.html
 
Boehringer Ingelheim pioneers biopharmaceuticals move to China
Jun. 6, 2013
 
Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology.
 
BravoBio got governmental grant
Jun. 9, 2013
 
The joint venture of BravoBio with Chinese Academy of Sciences passed the assessment of government and was granted with governmental funds this week. The sponsored project is "development of recombinant VLP vaccine against EV71 virus".
 
Headquarter of BravoBio moved to CBD of Shanghai
Jun. 10, 2013
 
The headquarter of BravoBio moved from Zhangjiang InnoPark to the municipal top CBD, Lujiazui Financial and Trade Zone. Next to Metro Line 4 and 6 as well as hundreds of restaurants, coffee bars and hotels, the new site is much more convenient for visitors and guests. The Century Park, the Oriental Pearl Tower, Shanghai Global Financial Center and the Pudong Bund are within 10 mins of driving or metro. Be our guest!
 
International Medica Foundation's Vaccine for Newborns Demonstrates Early Protection against Rotavirus
Jun. 19, 2013
 
The International Medica Foundation announced that for the first time in a large clinical trial of 998 young infants, its rotavirus vaccine was very effective when the first dose was administered to the babies in their first month of life and the second dose before they were two months old. This vaccination schedule provided protection to infants earlier in life than any of the existing rotavirus vaccines.
 
Sanofi joins GSK, MedImmune with 4-in-1 flu vaccine
Jun. 24, 2013
 
The 2013-2014 influenza season will be the first in which vaccines will contain two A and two B strains, and Sanofi Pasteur says it will be part of the change to the expanded program. The FDA has approved its 4-in-1 influenza vaccine in the U.S., joining two other quadrivalent vaccines already approved for the upcoming flu season. The approval helps solidify its place as revenue leader in the vaccine market.
The vaccine maker said the FDA has given the thumbs up to its Fluzone Quadrivalent, which is approved for children 6 months and older, adolescents and adults. Sanofi's jab now joins GlaxoSmithKline's (GSK) Fluarix Quadrivalent and AstraZeneca's (AZN) MedImmune 4-in-1 vaccines that are already approved.
This is will be the first flu season in which any quadrivalent vaccines will be available. They will contain two "A" strains and two "B" strains. An FDA panel has suggested the "B" strain from this season's vaccine be altered to better match the influenza strains that wreaked havoc in the U.S. this year. Three-strain vaccines will continue to be available but should over time be replaced with four-strain versions.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next